
    
      T-DXd will be administered at a dose of 5.4 mg/kg body weight once every three weeks in
      patients with newly diagnosed or progressive HER2 positive breast cancer brain metastases.
      Response rate by RANO-BM is defined the primary study endpoint.
    
  